|
³ª¿ìÆÊÄÁ¼³Æà |
½Å¾à°³¹ßȸ»ç ÀÓ»ó °æ·ÂÀÚ ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Country Medical Director/À¯·´°èÇÕÀÛÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
5³â¡è |
ä¿ë½Ã |
03.11 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
Á¦¾àÀÓÁ÷¿ø 114¸í ä¿ëÁ¤º¸
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.08 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Oncology´ã´ç °úÂ÷Àå±Þ)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
4³â¡è |
ä¿ë½Ã |
03.11 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
³ª¿ìÆÊÄÁ¼³Æà 2015.10.12ÀÏÀÚ Ã¤¿ëÁ¤º¸
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.03 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
ÀÇ·á±â±â Business Development
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
09.30 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
[¿Ü±¹°è ȸ»ç] Regulatory Affairs °æ·ÂÁ÷ (»ç¿ø/´ë¸®±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
01.02 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
Áß°ßÁ¦¾à»ç ÇØ¿Ü»ç¾÷ °æ·Â»ç¿ø ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
National Sales Manager(Aesthetics)/¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
10³â¡è |
ä¿ë½Ã |
10.01 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
12.03 |
|
|
(ÁÖ)ÀâÀ§µå |
[¿ÜÀÚÁ¦¾à/°³²¿ª] Àӻ󿬱¸ Coordinator(CRA)ä¿ë
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
¿Ü±¹°è Á¦¾àȸ»ç |
[¿ÜÀÚÁ¦¾à±â¾÷/»ï¼º¿ª] ÀÓ»ó(4»óÀÓ»ó)&PMS Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
10.30 |
|
|
(ÁÖ)Ç츮ƼÁö¼Ä¡ÄÚ¾î |
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
10.28 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
12.03 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
QC Specialist/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
12.01 |
|